Compare Sanofi SA (SNY) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Block Inc — how do they compare? Sanofi SA trades at $42.7 (market cap $104.06B), while Block Inc trades at $79.02 (market cap $48.12B). The key difference: Sanofi SA is far larger — about 2.2× Block Inc's market cap, and Sanofi SA pays a 5.61% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| SNY | XYZ | |
|---|---|---|
Market Cap | $104.06B | $48.12B |
Sector | Health | Technology |
52-Week High | $52.34 | $84.85 |
52-Week Low | $41.33 | $49.04 |
Enterprise Value | $124.09B | $43.03B |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
XYZ stock trades at $80.10, down 3.21% over 24 hours, with a bearish technical signal and support near $77. Recent earnings show mixed results, beating estimates in Q1 and Q2 2026 but missing in Q4 2025. Revenue growth is modest, with net income margin at 1.43% for 2025. The company is expanding into financial services, applying for a national trust bank charter to offer custody services, as reported by Business Wire on September 8, 2026.
The outlook is cautiously optimistic, with a consensus price target of $100.20 implying 25% upside, supported by 76% buy ratings from analysts. Risks include high P/E ratio of 143.04, regulatory hurdles for new banking initiatives, and volatile cash flows, with net cash flow negative $749 million in 2025. Institutional interest remains strong, with recent buying by Freestone Grove Partners LP noted in a Form 13F filing on August 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
